Patents by Inventor Maki DEGUCHI

Maki DEGUCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-EphA4 antibody
    Patent number: 11136400
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 5, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
  • Anti-EphA4 antibody
    Patent number: 11034769
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: June 15, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
  • Anti-EphA4 Antibody
    Publication number: 20210171644
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Application
    Filed: January 8, 2021
    Publication date: June 10, 2021
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Eiji INOUE, Akio YAMADA, Tomomi KAWAKATSU, Toshio IMAI, Maki DEGUCHI, Aki NAKATANI
  • Anti-EphA4 antibody
    Patent number: 10947313
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 16, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
  • Anti-EphA4 Antibody
    Publication number: 20210002378
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Application
    Filed: June 29, 2020
    Publication date: January 7, 2021
    Inventors: Eiji INOUE, Akio YAMADA, Tomomi KAWAKATSU, Toshio IMAI, Maki DEGUCHI, Aki NAKATANI